The Asia-Pacific market represents a $13 billion prestige skincare and luxury haircare market opportunity, with the Taiwan deal giving the…
Read More »Stem Cells
The company also reported record Q4 2023 revenue of $698,591, up 403% over the previous quarter. Elevai Labs Inc. (NASDAQ:…
Read More »
ELEVAI Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported its fiscal 2023 Q3 financial results.…
Read More »
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with…
Read More »
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announced today the signing of a licensing agreement…
Read More »